Cargando…
Pilot study to estimate the safety and effectiveness of hydroxyurea and methotrexate recurrent langerhans cell histiocytosis (LCH-HU-pilot)
Langerhans cell histiocytosis (LCH) is the most frequent type of histiocytosis and is characterized by both “inflammation/immune dysregulation” and “neoplastic disorder.” Although overall survival has remarkably improved through consecutive previous studies, the relapse-free survival rate is still o...
Autores principales: | Sakamoto, Kenichi, Kikuchi, Kayoko, Sako, Mayumi, Kato, Miho, Takimoto, Tetsuya, Shioda, Yoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771280/ https://www.ncbi.nlm.nih.gov/pubmed/36550910 http://dx.doi.org/10.1097/MD.0000000000031475 |
Ejemplares similares
-
Hepatic Langerhans Cell Histiocytosis (LCH) Presenting as a Harbinger of Multisystem LCH
por: Li, Hua, et al.
Publicado: (2020) -
A rare imaging presentation with multisystemic clinicopathological features of Langerhans cell histiocytosis: Case report and literature review
por: Li, Xiaofen, et al.
Publicado: (2023) -
Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions
por: Mitchell, Jenée, et al.
Publicado: (2022) -
Radiologic zebra line sign in a patient with Langerhans cell histiocytosis on bisphosphonate therapy
por: Sakamoto, Kenichi, et al.
Publicado: (2022) -
Polyclonal T-Cells Express CD1a in Langerhans Cell Histiocytosis (LCH) Lesions
por: West, Jennifer A., et al.
Publicado: (2014)